2024 annual financial data
CRISPR Therapeutics 2024 Operating margin
CRISPR Therapeutics 2024 operating margin with verified reported values.
Direct answer
Operating margin was -1,333.05%.
Operating income was -466,566,000 USD and net income was -366,252,000 USD.
Operating cash flow was -142,774,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 35,000,000 USD
- Operating income
- -466,566,000 USD
- Net income
- -366,252,000 USD
- Operating cash flow
- -142,774,000 USD